Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 2/20 | 0.56 |
| ▸ | FNTB | P49356 | 2/20 | 0.56 |
| ▸ | SQLE | Q14534 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10986149 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL16654337 | 0.98 | KMT2A (0.60) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL1685900 | 0.98 | KMT2A (0.60) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL1685901 | 0.98 | KMT2A (0.60) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL331561 | 0.84 | KMT2A (0.59) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL331563 | 0.84 | KMT2A (0.59) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL794675 | 0.83 | KMT2A (0.58) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL794674 | 0.83 | KMT2A (0.58) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11787183 | 0.83 | KMT2A (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11787182 | 0.83 | KMT2A (0.44) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365169-B2 | Method for synthesising vitamin A | ADISSEO FRANCE S.A.S. (FR) | 2022-06-21 | — | — | US | claimed |
| US-20210309597-A1 | METHOD FOR SYNTHESISING VITAMIN A | ADISSEO FRANCE S.A.S. (FR) | 2021-10-07 | — | — | US | claimed |
| EP-3841088-A1 | METHOD FOR VITAMIN A SYNTHESIS | Adisseo France S.A.S. (FR) | 2021-06-30 | — | — | EP | claimed |
| WO-2020038858-A1 | METHOD FOR VITAMIN A SYNTHESIS | ADISSEO FRANCE S.A.S. (FR) | 2020-02-27 | — | — | WO | claimed |
| US-11365169-B2 | Method for synthesising vitamin A | ADISSEO FRANCE S.A.S. (FR) | 2022-06-21 | — | — | US | disclosed |
| US-20210309597-A1 | METHOD FOR SYNTHESISING VITAMIN A | ADISSEO FRANCE S.A.S. (FR) | 2021-10-07 | — | — | US | disclosed |
| EP-3841088-A1 | METHOD FOR VITAMIN A SYNTHESIS | Adisseo France S.A.S. (FR) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020038858-A1 | METHOD FOR VITAMIN A SYNTHESIS | ADISSEO FRANCE S.A.S. (FR) | 2020-02-27 | — | — | WO | disclosed |
| EP-0414106-B1 | Process for the preparation of terpenes | EISAI CO LTD (JP) | 1996-03-27 | — | — | EP | disclosed |
| CN-1026579-C | Process for prepn. of terpenes | EISAI CO LTD (JP) | 1994-11-16 | — | — | CN | disclosed |
| US-5073659-A | Alkylation, Grignard reagent, zinc chloride catalyst and coppe r compound | EISAI CO., LTD. (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0414106-A2 | Process for the preparation of terpenes | Eisai Co., Ltd. (JP) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309597-A1 | METHOD FOR SYNTHESISING VITAMIN A | CYP2R1, NR1H3, NR1H2 | KMT2A 1599/4885MAPT 4659/4885MEN1 3743/4885 |
| US-11365169-B2 | Method for synthesising vitamin A | CYP2R1, NR1H3, NR1H2 | KMT2A 1487/4885MAPT 4773/4885MEN1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.